On December 26, Teva Pharmaceutical (TEVA) stock closed at $15.82, a rise of ~8.43% from its close of $14.59 on December 24. The stock closed at $21.94 on November 23 and reached $15.82 at the close of market on December 26, reflecting a ~28% fall in the past month.
On December 26, Teva Pharmaceutical stock closed at $15.82, ~39% down from its 52-week high of $25.96 on August 21.
In December, the FDA approved Teva Pharmaceutical’s ProAir Digihaler inhalation powder and digital inhaler for the treatment of individuals with asthma and chronic obstructive pulmonary disorder. The ProAir Digihaler is the first—and currently the only—digital inhaler with built-in sensors that connect to a patient’s mobile application to deliver information related to inhaler use. The device has been approved for the prevention and treatment of the above indications in patients who are over four years old.
According to the National Center for Health Statistics, currently, ~25 million Americans have asthma and are in need of inhalers as a therapy regimen.
Of the 23 analysts tracking Teva Pharmaceutical in December, one has recommended a “strong buy,” and three have recommended “buys.” Fifteen analysts have recommended “holds,” while four have recommended “sells” on the stock.
As of December 27, Teva Pharmaceutical has a consensus 12-month target price of $22.94, which reflects a potential ~45.01% return on investment over the next 12 months.
In December, of the 17 analysts tracking Mylan (MYL), ~76% have given it “buys.” Among the 23 analysts tracking Allergan (AGN), ~74% have given it “buys.” Of the 17 analysts tracking Bausch Health (BHC), ~41% have given it “buys.”
On December 27, Mylan, Allergan, and Bausch Health had consensus 12-month target prices of $44.87, $211.11, and $29.86, respectively, potential returns of ~61.93%, ~85.24%, and ~58.41%, respectively, over the next 12 months.